Verano (VRNO) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $217 million, down 2.6% sequentially and 9.6% year-over-year, with a net loss of $43 million and adjusted EBITDA of $64 million (30% margin), impacted by supply constraints, competition, and 280E tax treatment.

• Retail/wholesale revenue split was 64.5%/35.5%, with continued expansion in Florida, Virginia, and Arizona, and integration of new acquisitions requiring minimal CapEx.

• Retail footprint expanded to 152 dispensaries across 14 states, with 1.1 million sq. ft. of cultivation capacity.

• Focus on cost management, margin preservation, and efficiency improvements across the organization.

• Optimism remains high for regulatory progress, including potential federal cannabis rescheduling and bipartisan support for reform.

Financial highlights

• Q3 2024 revenue was $217 million, with gross profit of $109 million (50% margin), SG&A expenses of $92 million (43% of revenue), and adjusted EBITDA of $64 million (30% margin).

• Net loss was $43 million (20% of revenue), impacted by supply issues, competition, and 280E tax treatment.

• Cash and cash equivalents were $65 million as of September 30, 2024.

• Year-to-date cash flow from operations was $69 million; $85 million spent on CapEx, mainly for Florida expansion.

• Total debt stood at $420 million as of September 30, 2024.

Outlook and guidance

• Organic revenue trends from Q3 expected to persist into Q4, with some offset from holiday season lift.

• Retail sales anticipated to be flat or slightly up in Q4; wholesale faces headwinds due to stricter credit policies.

• Management optimistic about growth in Florida and potential catalysts from regulatory changes, including rescheduling and banking reforms.

• Major CapEx projects scaled back for 2025, with focus shifting to minor store refreshes, automation, and efficiency projects.

• Continued cost-cutting and efficiency initiatives expected over the next few quarters.